Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

Update on Topical Treatments for Psoriasis: The Role of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam.

Puig L, Carretero G.

Actas Dermosifiliogr. 2018 Jul 18. pii: S0001-7310(18)30321-1. doi: 10.1016/j.ad.2018.05.010. [Epub ahead of print] English, Spanish.

PMID:
30031488
2.

Synthesis, biophysical and functional studies of two BP100 analogues modified by a hydrophobic chain and a cyclic peptide.

Carretero GPB, Saraiva GKV, Cauz ACG, Rodrigues MA, Kiyota S, Riske KA, Dos Santos AA, Pinatto-Botelho MF, Bemquerer MP, Gueiros-Filho FJ, Chaimovich H, Schreier S, Cuccovia IM.

Biochim Biophys Acta. 2018 Aug;1860(8):1502-1516. doi: 10.1016/j.bbamem.2018.05.003. Epub 2018 May 9.

PMID:
29750913
3.

Lymph Node Dissection in Patients With Melanoma and Sentinel Lymph Node Metastasis: An Updated, Evidence-Based Decision Algorithm.

Moreno-Ramírez D, Boada A, Ferrándiz L, Samaniego E, Carretero G, Nagore E, Redondo P, Ortiz-Romero P, Malvehy J, Botella-Estrada R; miembros del Grupo Español de Dermato-Oncología y Cirugía. Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2018 Jun;109(5):390-398. doi: 10.1016/j.ad.2018.02.008. Epub 2018 Apr 9. English, Spanish.

PMID:
29650221
4.

Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study.

Descalzo MA, Carretero G, Ferrándiz C, Rivera R, Daudén E, Gómez-García FJ, de la Cueva P, Herrera-Ceballos E, Belinchón I, López-Estebaranz JL, Alsina M, Sánchez-Carazo JL, Ferrán M, Baniandrés O, Carrascosa JM, Llamas-Velasco M, Ruiz-Genao D, Herrera-Acosta E, Muñoz-Santos C, García-Doval I; Biobadaderm Study Group.

J Am Acad Dermatol. 2018 Apr;78(4):798-800. doi: 10.1016/j.jaad.2017.10.051. Epub 2017 Nov 13. No abstract available.

PMID:
29146129
5.

Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.

Carretero G, Puig L, Carrascosa JM, Ferrándiz L, Ruiz-Villaverde R, de la Cueva P, Belinchon I, Vilarrasa E, Del Rio R, Sánchez-Carazo JL, López-Ferrer A, Peral F, Armesto S, Eiris N, Mitxelena J, Vilar-Alejo J, A Martin M, Soria C; from the Spanish Group of Psoriasis.

J Dermatolog Treat. 2018 Jun;29(4):334-346. doi: 10.1080/09546634.2017.1395794. Epub 2017 Nov 21. Review.

PMID:
29099667
6.

Skin Cancer and the Dermatologist: Reflections on the Position Taken by the Spanish Society of Medical Oncology (SEOM).

Moreno-Ramírez D, Nagore E, Botella-Estrada R, Carretero G, Puig S, Redondo P, Rodrígurez-Prieto MA, Samaniego E, Sanmartín O, Malvehy J.

Actas Dermosifiliogr. 2017 Oct;108(8):704-707. doi: 10.1016/j.ad.2017.06.003. Epub 2017 Jul 10. English, Spanish. No abstract available.

PMID:
28705520
7.

Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.

Belinchón I, Ramos JM, Carretero G, Ferrándiz C, Rivera R, Daudén E, De la Cueva-Dobao P, Gómez-García FJ, Herrera-Ceballos E, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Llamas-Velasco M, Ortiz PL, García-Doval I, Descalzo MA; Biobadaderm Study Group.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1700-1708. doi: 10.1111/jdv.14314. Epub 2017 Jun 6.

PMID:
28485816
8.

Reliability of the MDi Psoriasis® Application to Aid Therapeutic Decision-Making in Psoriasis.

Moreno-Ramírez D, Herrerías-Esteban JM, Ojeda-Vila T, Carrascosa JM, Carretero G, de la Cueva P, Ferrándiz C, Galán M, Rivera R, Rodríguez-Fernández L, Ruiz-Villaverde R, Ferrándiz L.

Actas Dermosifiliogr. 2017 Sep;108(7):650-656. doi: 10.1016/j.ad.2017.02.009. Epub 2017 Apr 4. English, Spanish.

PMID:
28385425
9.

Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry.

Pérez-Plaza A, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Llamas-Velasco M, Rivera R, Jiménez-Puya R, García-Doval I, Descalzo MA; Biobadaderm Study Group.

J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1021-1028. doi: 10.1111/jdv.14188. Epub 2017 Apr 12.

PMID:
28252811
10.

Peptoids successfully inhibit the growth of gram negative E. coli causing substantial membrane damage.

Mojsoska B, Carretero G, Larsen S, Mateiu RV, Jenssen H.

Sci Rep. 2017 Feb 14;7:42332. doi: 10.1038/srep42332.

11.

Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.

Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Llamas M, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group.

J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1942-1950. doi: 10.1111/jdv.13682. Epub 2016 Jun 22.

PMID:
27329511
12.

Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries.

Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, Ferrándiz C, Stern RS, Naldi L; Psonet Network.

J Am Acad Dermatol. 2017 Feb;76(2):299-308.e16. doi: 10.1016/j.jaad.2016.07.039. Epub 2016 Sep 29.

PMID:
27693008
13.

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.

Dávila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa JM, Vanaclocha F, Gómez-García FJ, De la Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, López-Estebaranz JL, Alsina M, Sánchez-Carazo JL, Ferrán M, Torrado R, Ferrandiz C, Rivera R, Llamas M, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group.

J Invest Dermatol. 2017 Feb;137(2):313-321. doi: 10.1016/j.jid.2016.08.034. Epub 2016 Sep 25.

14.

IL17RA gene variants and anti-TNF response among psoriasis patients.

Batalla A, Coto E, Gómez J, Eirís N, González-Fernández D, Gómez-De Castro C, Daudén E, Llamas-Velasco M, Prieto-Perez R, Abad-Santos F, Carretero G, García FS, Godoy YB, Cardo LF, Alonso B, Iglesias S, Coto-Segura P.

Pharmacogenomics J. 2018 Jan;18(1):76-80. doi: 10.1038/tpj.2016.70. Epub 2016 Sep 27.

PMID:
27670766
15.

Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry.

Galiano Mejías S, Carretero G, Ferrandiz C, Vanaclocha F, Daudén E, Gómez-García FJ, Herrera-Ceballos E, Belinchón-Romero I, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Rivera R, Llamas-Velasco M, Jiménez-Puya R, Mendiola MV, Ruiz-Genao D, Descalzo MA, de la Cueva Dobao P; del grupo Biobadaderm.

Actas Dermosifiliogr. 2017 Jan - Feb;108(1):52-58. doi: 10.1016/j.ad.2016.08.003. Epub 2016 Sep 20. English, Spanish.

PMID:
27658689
16.

Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations.

Carrascosa JM, de la Cueva P, Ara M, Puig L, Bordas X, Carretero G, Ferrándiz L, Sánchez-Carazo JL, Daudén E, López-Estebaranz JL, Vidal D, Herranz P, Jorquera E, Coto-Segura P, Ribera M.

Actas Dermosifiliogr. 2016 Apr;107(3):194-206. doi: 10.1016/j.ad.2015.10.005. Epub 2015 Nov 21. Review. English, Spanish.

PMID:
26614486
17.

Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort.

García-Doval I, Pérez-Zafrilla B, Ferrandiz C, Carretero G, Daudén E, de la Cueva P, Gómez-García FJ, Herrera-Ceballos E, Belinchón-Romero I, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Rivera R, Vanaclocha F; BIOBADADERM Study Group.

J Dermatolog Treat. 2016;27(3):203-9. doi: 10.3109/09546634.2015.1088130. Epub 2015 Sep 25.

PMID:
26367799
18.

Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.

Carrascosa JM, Rivera N, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, Gómez-García FJ, De-la-Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, Alsina M, Sánchez-Carazo JL, Ferrán M, Lopez-Estebaranz JL, Pérez-Zafrilla B, Llamas M, Rivera R, Ferrándiz C; BIOBADADERM Study Group.

Actas Dermosifiliogr. 2015 Oct;106(8):638-43. doi: 10.1016/j.ad.2015.04.013. Epub 2015 Jun 30. English, Spanish.

PMID:
26141003
19.

Biosimilars in Dermatology: Current Situation (Part II).

Puig L, Carretero G, Daudén E, Ferrándiz C, Marrón SE, Martorell A, Pérez-Suárez B, Rodriguez-Cerdeira C, Ruiz-Villaverde R, Sánchez-Carazo JL, Velasco M; en nombre del Grupo de Psoriasis de Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2015 Sep;106(7):550-4. doi: 10.1016/j.ad.2015.04.008. Epub 2015 Jun 3. Review. English, Spanish.

PMID:
26049964
20.

Biosimilars in Dermatology: Current Situation (Part I).

Puig L, Carretero G, Daudén E, Ferrándiz C, Marrón SE, Martorell A, Pérez-Suárez B, Rodriguez-Cerdeira C, Ruiz-Villaverde R, Sánchez-Carazo JL, Velasco M; en nombre del Grupo de Psoriasis de Academia Española de Dermatología y Venereología.

Actas Dermosifiliogr. 2015 Sep;106(7):545-9. doi: 10.1016/j.ad.2015.04.006. Epub 2015 May 16. Review. English, Spanish.

PMID:
25987472

Supplemental Content

Loading ...
Support Center